1 – 4 of 4
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
(
- Contribution to journal › Article
- 2022
-
Mark
22nd meeting of the European Society of Gynaecological Oncology (ESGO 2021) report
(
- Contribution to journal › Article
- 2021
-
Mark
Report from the European Society of Gynaecological Oncology (ESGO) 2020 State-of-the-Art Virtual Meeting
(
- Contribution to journal › Article
- 2016
-
Mark
Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-Expressing platinum-resistant ovarian Cancer (PENELOPE)
(
- Contribution to journal › Article